Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484070 | 0.87 | CYP1A1 (0.45) | IDO1CYP19A1PIM1TDO2CDK5 | |
| SCHEMBL1484245 | 0.86 | KDM4E (0.41) | IDO1CYP19A1PIM1CDK5CDK5R1 | |
| SCHEMBL1484601 | 0.83 | MAPT (0.49) | IDO1PIM1KDM4EALDH1A1 | |
| SCHEMBL1425121 | 0.80 | MAPT (0.37) | IDO1PIM1CDK5CDK5R1KDM4E | |
| SCHEMBL1484209 | 0.79 | CYP19A1 (0.46) | IDO1CYP19A1PIM1CDK5CDK5R1 | |
| SCHEMBL1424267 | 0.79 | PIM1 (0.39) | IDO1CYP19A1PIM1CDK5CDK5R1 | |
| SCHEMBL1483695 | 0.79 | KDM4E (0.40) | CYP19A1PIM1CDK5CDK5R1KDM4E | |
| SCHEMBL1483994 | 0.79 | CYP1A2 (0.37) | IDO1PIM1CDK5CDK5R1KDM4E | |
| SCHEMBL1422576 | 0.76 | MAPT (0.41) | IDO1CYP19A1PIM1CDK5CDK5R1 | |
| SCHEMBL1425629 | 0.76 | CDK5 (0.46) | IDO1CYP19A1PIM1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | IDO1 9/4885CYP19A1 3222/4885PIM1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.